In a significant interim decision, the U.S. Supreme Court has allowed women to continue accessing the abortion pill mifepristone through telehealth consultations and mail delivery. The ruling maintains the current system while legal challenges continue in lower courts, particularly a case led by officials in Louisiana.
Court Blocks Lower Court Restrictions for Now
The Supreme Court paused a May 1 ruling by the 5th U.S. Circuit Court of Appeals, which had required patients to obtain mifepristone through in-person doctor visits. By issuing this stay, the high court has effectively preserved broader access to the medication for the time being.
The justices did not provide an explanation for their decision and did not disclose how individual members voted. However, Justices Clarence Thomas and Samuel Alito publicly dissented.
Legal Battle Returns to Appeals Court
The case will now return to the New Orleans-based federal appeals court, which will consider the broader legal arguments raised by Louisiana officials seeking to restrict access to the drug.
Notably, the Supreme Court declined requests from both sides to immediately hear the case, signaling that the issue is likely to return to the high court at a later stage after further legal review.
Strong Reactions from Both Sides
Louisiana Attorney General Liz Murrill criticized the decision, calling it “shocking” and confirming that the state will continue its legal fight.
Meanwhile, anti-abortion groups argued that allowing mail-order access to mifepristone undermines earlier Supreme Court rulings, including the landmark 2022 decision that overturned the constitutional right to abortion.
Telehealth Abortions Have Grown Rapidly
Access to mifepristone through telehealth has expanded significantly in recent years. During the COVID-19 pandemic, regulations were relaxed to allow remote consultations, and in 2023, the FDA made those changes permanent.
Medication abortions now account for over 60% of all abortions in the United States. According to research groups, nearly one in four abortions in 2025 were conducted via telehealth, highlighting the growing reliance on remote healthcare services.
Key Details at a Glance
| Feature | Details |
|---|---|
| Decision | Telehealth access allowed to continue |
| Drug | Mifepristone |
| Court Action | Pause on lower court ruling |
| Next Step | Case returns to appeals court |
| Dissenting Justices | Clarence Thomas, Samuel Alito |
| Access Method | Telehealth & mail delivery |
| Status | Temporary (not final ruling) |
What Happens Next
The Supreme Court’s decision does not settle the issue permanently but ensures that current access to mifepristone remains unchanged for now. The outcome of the appeals court case will play a crucial role in determining the future of telehealth-based abortion access in the United States.
With the legal battle ongoing, the issue is expected to return to the Supreme Court, potentially setting up another major ruling on abortion access in the near future.